目的探讨壮骨止痛方对骨质疏松大鼠核因子κB受体活化因子(receptor activator of NF-κB,RANK)、核因子κB受体活化因子配体(receptoractivator of NF-κB ligand,RANKL)和骨保护素(osteoprotegrin,OPG)表达的影响。方法将实验动物分...目的探讨壮骨止痛方对骨质疏松大鼠核因子κB受体活化因子(receptor activator of NF-κB,RANK)、核因子κB受体活化因子配体(receptoractivator of NF-κB ligand,RANKL)和骨保护素(osteoprotegrin,OPG)表达的影响。方法将实验动物分为假手术组、模型组、壮骨止痛方高剂量治疗组、壮骨止痛方低剂量治疗组、雌二醇组5组,用酶联免疫免法测定大鼠血清中OPG、RANKL的水平。结果模型组大鼠血清OPG降低、RANKL水平升高,经壮骨止痛方药物干预后,大鼠血清OPG水平明显下降、RANKL水平明显下降。结论壮骨止痛方药物可以降低大鼠血清RANKL/OPG的比值,激活RANKL/RANK/OPG信号系统,达到预防治疗骨质疏松的作用。展开更多
Desmoid-type fibromatosis (DF) is a rare, locally invasive, non-metastasizing soft tissue proliferation derived from mesenchymal progenitor cells. The incidence of DF is 2 to 4 per million per year in the general popu...Desmoid-type fibromatosis (DF) is a rare, locally invasive, non-metastasizing soft tissue proliferation derived from mesenchymal progenitor cells. The incidence of DF is 2 to 4 per million per year in the general population and typically affects adults between the ages of 35 - 40. Desmoid-type fibromatosis can either be sporadic or associated with mutation in the adenomatous polyposis coli gene. Trauma, surgery, pregnancy, and oral contraceptives have been identified as risk factors for the development of desmoid-type fibromatosis. MRI is the standard for image characterization, and CT image-guided core needle biopsy for diagnosis. “Wait and see” is the current management recommendation, and studies of y-secretase inhibitors and tyrosine kinase inhibitors have shown promise in the treatment of desmoid-type fibromatosis. This report presents a case of rare right shoulder desmoid type fibromatosis in a 48-year-old male that was missed on an initial workup including EMG/NCS and shoulder MRI, and demonstrates the importance of revisiting the diagnostic process if a former workup has yielded an unclear clinical picture.展开更多
文摘目的探讨壮骨止痛方对骨质疏松大鼠核因子κB受体活化因子(receptor activator of NF-κB,RANK)、核因子κB受体活化因子配体(receptoractivator of NF-κB ligand,RANKL)和骨保护素(osteoprotegrin,OPG)表达的影响。方法将实验动物分为假手术组、模型组、壮骨止痛方高剂量治疗组、壮骨止痛方低剂量治疗组、雌二醇组5组,用酶联免疫免法测定大鼠血清中OPG、RANKL的水平。结果模型组大鼠血清OPG降低、RANKL水平升高,经壮骨止痛方药物干预后,大鼠血清OPG水平明显下降、RANKL水平明显下降。结论壮骨止痛方药物可以降低大鼠血清RANKL/OPG的比值,激活RANKL/RANK/OPG信号系统,达到预防治疗骨质疏松的作用。
文摘Desmoid-type fibromatosis (DF) is a rare, locally invasive, non-metastasizing soft tissue proliferation derived from mesenchymal progenitor cells. The incidence of DF is 2 to 4 per million per year in the general population and typically affects adults between the ages of 35 - 40. Desmoid-type fibromatosis can either be sporadic or associated with mutation in the adenomatous polyposis coli gene. Trauma, surgery, pregnancy, and oral contraceptives have been identified as risk factors for the development of desmoid-type fibromatosis. MRI is the standard for image characterization, and CT image-guided core needle biopsy for diagnosis. “Wait and see” is the current management recommendation, and studies of y-secretase inhibitors and tyrosine kinase inhibitors have shown promise in the treatment of desmoid-type fibromatosis. This report presents a case of rare right shoulder desmoid type fibromatosis in a 48-year-old male that was missed on an initial workup including EMG/NCS and shoulder MRI, and demonstrates the importance of revisiting the diagnostic process if a former workup has yielded an unclear clinical picture.
